Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ACP1 | P24666 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 3/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.31 |
| ▸ | NOS3 | P29474 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8989374 | 0.91 | MAPT (0.38) | TAAR1HTR1DCYP3A4CYP1A2CYP2C9 | |
| SCHEMBL8989302 | 0.91 | TAAR1 (0.37) | TAAR1HTR1DCYP3A4CYP1A2CYP2C9 | |
| SCHEMBL10742019 | 0.90 | MAPT (0.37) | TAAR1HTR1DCYP3A4CYP1A2CYP2C9 | |
| SCHEMBL9641608 | 0.85 | TAAR1 (0.33) | TAAR1MEN1LMNAMAPTKMT2A | |
| SCHEMBL2103783 | 0.84 | TAAR1 (0.46) | TAAR1HTR1DCYP3A4CYP1A2CYP2C9 | |
| SCHEMBL9641579 | 0.83 | TAAR1 (0.32) | TAAR1ACP1 | |
| SCHEMBL10745477 | 0.82 | HRH3 (0.40) | HTR1DMEN1MAPTKMT2APARP1 | |
| SCHEMBL31248590 | 0.81 | SLC6A2 (0.34) | TAAR1MEN1LMNAMAPTKMT2A | |
| SCHEMBL10743458 | 0.81 | SLC6A2 (0.34) | TAAR1MEN1LMNAMAPTKMT2A | |
| SCHEMBL10741610 | 0.81 | TAAR1 (0.44) | TAAR1MEN1MAPTKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004230-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO (DE) | 2012-01-05 | — | — | US | claimed |
| US-20100204233-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO | 2010-08-12 | — | — | US | claimed |
| EP-2094668-A2 | 4-IMIDAZOLINES AS TAAR'S LIGANDS | F. Hoffmann-Roche AG (CH) | 2009-09-02 | — | — | EP | claimed |
| WO-2008074679-A2 | 4-IMIDAZOLINES AS TAAR'S LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | WO | claimed |
| US-20080146523-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-06-19 | — | — | US | claimed |
| EP-0719139-A1 | USE OF CENTRALLY ACTIVE ALPHAAGONISTS FOR INHIBING POSTRAUMATIC METABOLIC STRESS | Dr. Karl Thomae GmbH (DE) | 1996-07-03 | — | — | EP | claimed |
| WO-1995003798-A2 | USE OF CENTRALLY EFFECTIVE α-2 AGONISTS FOR INHIBITING POSTAGGRESSION METABOLISM | BOEHRINGER INGELHEIM INT (DE) | 1995-02-09 | — | — | WO | claimed |
| EP-0170193-B1 | FEEDSTUFF ADDITIVE FOR THE GROWTH PROMOTING OF AGRICULTURAL USEFUL ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1991-12-27 | — | — | EP | claimed |
| EP-0437030-A2 | 4-Substituted imidazoles for lowering intraocular pressure | ORION-YHTYMÀ OY (FI) | 1991-07-17 | — | — | EP | claimed |
| EP-0170193-A2 | Feedstuff additive for the growth promoting of agricultural useful animals | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1986-02-05 | — | — | EP | claimed |
| US-4568686-A | Substituted imidazoles and their use | FARMOS YHTYMA OY (FI) | 1986-02-04 | — | — | US | claimed |
| EP-0034473-B1 | SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Farmos-Yhtyma Oy (FI) | 1983-09-21 | — | — | EP | claimed |
| EP-0034473-A2 | Substituted imidazoles, their preparation and pharmaceutical compositions containing the same | Farmos-Yhtyma Oy (FI) | 1981-08-26 | — | — | EP | claimed |
| US-8399463-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120004230-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20100204233-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO | 2010-08-12 | — | — | US | disclosed |
| US-4568686-A | Substituted imidazoles and their use | FARMOS YHTYMA OY (FI) | 1986-02-04 | — | — | US | disclosed |
| EP-0034473-B1 | SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Farmos-Yhtyma Oy (FI) | 1983-09-21 | — | — | EP | disclosed |
| EP-0034473-A2 | Substituted imidazoles, their preparation and pharmaceutical compositions containing the same | Farmos-Yhtyma Oy (FI) | 1981-08-26 | — | — | EP | disclosed |
| EP-0034474-A1 | Substituted imidazoles, their preparation and pharmaceutical compositions containing the same | Farmos-Yhtyma Oy (FI) | 1981-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204233-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | TAAR1 1/4885HTR1D 354/4885CYP3A4 780/4885 |
| US-20120004230-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | TAAR1 1/4885HTR1D 354/4885CYP3A4 780/4885 |
| US-20080146523-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | TAAR1 1/4885HTR1D 354/4885CYP3A4 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.